Dihexa is a small, chemically modified peptide derived from angiotensin IV, a fragment of the hormone system that helps regulate blood pressure. It is not FDA-approved for any use, and there is no FDA-approved product that contains it. The FDA has said it has not identified any human exposure data for dihexa by any route.
Dihexa was developed by researchers at Washington State University (WSU), who designed it to be more stable and longer-lasting in the body than angiotensin IV itself.
The WSU group proposed that dihexa acts by strengthening the signal of hepatocyte growth factor (HGF), a signaling protein, at its receptor, called c-Met. HGF signaling is involved in cell growth and in the formation of connections between nerve cells, which is why the group studied dihexa in memory models.
That proposed mechanism has been undermined. On April 29, 2025, the Journal of Pharmacology and Experimental Therapeutics retracted the group's 2014 paper linking the memory and synapse effects of angiotensin IV-derived peptides to the HGF/c-Met system. The retraction notice says a WSU investigation found falsified and/or fabricated data in parts of that paper.
Research on dihexa has been preclinical, meaning laboratory and animal work, including rat and mouse models of memory impairment. No human study of dihexa has been published, so its effects, side effects and long-term safety in people are unknown.
The research also led to a company, originally called M3 Biotechnology and later renamed Athira Pharma. In 2021 a special committee of Athira's board concluded that its then chief executive, a former WSU doctoral student in the research group, had altered images in her 2011 dissertation and in at least four research papers, and she left the company. Findings like these are a reason to read older dihexa claims with caution.
Current status: Not FDA-approved.
Compounding: The FDA had listed dihexa acetate in Category 2 of its interim 503A lists, the group of bulk substances that raise significant safety risks. In April 2026 it was one of 12 peptides removed from Category 2 after the nominators withdrew their nominations. The FDA has said its Pharmacy Compounding Advisory Committee will discuss dihexa acetate before the end of February 2027. Removal from Category 2 does not by itself make a substance eligible for compounding: as of the FDA's May 14, 2026 update, dihexa is not on the 503A bulks list and is not in Category 1.
Products labeled "for research purposes only" or "not for human consumption" are not approved drugs, so their identity, purity and safety have not been reviewed by the FDA.
In its safety summary, the FDA wrote that it has not identified any human exposure data on drug products containing dihexa acetate, and that it lacks important information about any safety issues, including whether dihexa would cause harm if given to people.
Because there are no human data, there is no established safe amount, no known side-effect profile and no information on interactions with other medicines.
Dihexa is not named on the World Anti-Doping Agency (WADA) 2026 Prohibited List. The list's S0 class covers any pharmacological substance not addressed elsewhere on the list that has no current approval by any government health authority for human therapeutic use. Athletes should check with their anti-doping organization before using any unapproved compound.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply dihexa, and we do not point readers to anyone who does.
For personal medical questions, including concerns about memory or thinking, the right person to ask is a licensed healthcare provider, who can look for underlying causes and discuss options that have been studied in people.
See the full list of compound profiles in the Peptide Guide. Other compounds marketed for cognition include Semax and Selank. For the legal background, read whether peptides are legal in the U.S.